Home Search Abstracts Browse Sessions Program Committee Conference Webcasts Contact Us


Session 83   Poster Abstracts
Antiretroviral Agents in Resource Limited Settings
Wednesday, 1:30 - 3:30 pm
Poster Hall
580
Protease and Reverse Transcriptase Polymorphisms in Treatment-naďve Individuals Infected with HIV-1 Subtype C in Southern Africa
O K'Aluoch*1, R Donovan1, E Liu1, C Gray2, C Williamson3, and H Sheppard1
1California Dept. of Hlth. Svcs., Richmond, USA; 2Natl. Inst. for Communicable Diseases, Johannesburg, South Africa; and 3Univ. of Cape Town, South Africa
581
Antiretroviral Drug Content in Products from Developing Countries
S Penzak*1, E Acosta2, M Turner2, J Tavel3, and H Masur1
1Clin. Ctr., NIH, DHHS, Bethesda, MD, USA; 2Univ. of Alabama at Birmingham, USA; and 3NIAID, NIH, DHHS, Bethesda, MD, USA
582Quality Assurance of Generic Antiretroviral Formulations in India
G Ramachandran*1, E S Perloff2, L L von Moltke2, S Swaminathan1, and D J Greenblatt2
1Tuberculosis Res. Ctr., Indian Council of Med. Res., Chennai, India and 2Tufts Univ. Sch. of Med., Boston, MA, USA
583
Generic AZT vs d4T In HIV/TB Co-infection in Clinical Practice In India: An Observational Study
D Saple*1, and S Vaidya2
1Grant Med. Coll. & G T Hosp., Mumbai, India and 2K J Somaiya Hosp. and Res. Ctr., Mumbai, India
584
Nevirapine- vs Efavirenz-based Antiretroviral Treatment in Naive Indian patients: Comparision of Effectiveness in a Clinical Cohort
A K Patel*1, S Pujari2, K K Patel1, J K Patel3, N Shah1, B Patel4, and N Gupte5
1Sterling Hosp., Ahmedabad, India; 2Ruby Hall Clin., Pune, India; 3Adit Diagnostic and Molecular Biology Ctr., Ahmedabad, India; 4Shashwat Microbiology, Ahmedabad, India; and 5Consultant Biostatistician, Pune, India
585
Botswana/Baylor Antiretroviral Assessment Trial Experience with Antiretroviral Medications in a Resource Constrained Setting
H Schwarzwald*1, G Anabwani2,3, D Bowman1, N Calles1, S Cron1, D Evans1, M Ferris1, H Jibril3, C Kozinetz1, K Mathuba3, S Mothobogwa3, O Tshume3, O Yarosh3, X Zhu1, and M Kline1
1Baylor Coll. of Med., Houston, TX, USA; 2Baylor Coll. of Med., Gaborone, Botswana; and 3Botswana-Baylor Children's Clin. Ctr. of Excellence, Gaborone
586Weight and Body Shape Changes Associated with Antiretroviral Therapy in South India: Initial Prospective Analysis
S Saghayam*1, N Kumarasamy1, S Solomon1, J Anitha1, S Chaguturu2, K Mayer2, T Flanigan2, and C Wanke3
1YRG Ctr. for AIDS Res. and Education, Chennai, India; 2Miriam Hosp., Brown Univ., Providence, RI, USA; and 3Tufts Univ. Sch. of Med., Boston, MA, USA
587Initiation of HAART in Advanced HIV-infected Patients with CD4 <50 Cells/mm3 in a Resource-limited Setting: Efficacy and Tolerability
S Sungkanuparph*, A Vibhagool, S Kiertiburanakul, W Manosuthi, and W Kiatatchasai
Ramathibodi Hosp., Mahidol Univ. Faculty of Med., Bangkok, Thailand
588
Virologic and Immunologic Response to Highly Active Antiretroviral Therapy among HIV-infected Children in Cote d'Ivoire
F Diomande1, H Lago1, D Hanson2, C Phares*3, F Anthony4, C Maurice1, B Monga1,5, J Nkengasong1,5, M Laga1, E Bissagnéné6, T Ellerbrock7, and M Nolan1,5
1Project RETRO-CI, Abidjan, Ivory Coast; 2CDC, Atlanta, GA, USA; 3Univ. of California, Berkeley, USA; 4Univ. Hosp. of Yopougon, Abidjan, Ivory Coast; 5CDC, Atlanta, GA, USA; 6Drug Access Initiative, Ministry of Hlth., Abidjan, Ivory Coast; and 7CDC, Global AIDS Prgm., Atlanta, GA, USA
589Low-cost Strategies to Monitor Highly Active Antiretroviral Therapy in Resource-limited Settings
N Kumarasamy*1, S K Chaguturu2, P Balakrishnan1, K H Mayer2, S Solomon1, and T P Flanigan2
1YRG Ctr. for AIDS Res. and Education, Chennai, India and 2Miriam Hosp., Brown Med. Sch., Providence, RI, USA
590Development of an Affordable HIV-1 Viral Load Assay for Reference Laboratories in a Resource Constraned Settings
N Rekhviashvili*, G Stevens, and W Stevens
Natl. Hlth. Lab. Svc. and the Univ. of the Witwatersrand, Johannesburg South Africa
591Clinical Monitoring of Cotrimoxazole, Duovir, and Nevimmune (Generic HAART) among Men and Women with AIDS in Zimbabwe
D Bhattacharaya1,2, G Kadzirange*1,2, L S Zijenah1, E Matsikire3, S Moyo3,4, T Kufa3,4, O Tobaiwa3, M Chirenje1,2, C Maponga1, R Machekano1,5, D A Katzenstein2, and Zimbabwe AIDS Prevention Project
1Univ. of Zimbabwe, Harare; 2Stanford Univ., CA, USA; 3Zimbabwe AIDS Prevention Project, Harare; 4Medicin Sans Frontier, Harare, Zimbabwe; and 5San Mateo County AIDS Prgm., CA, USA
592CD4 Response to HAART in Previously Untreated Adults with HIV Infection in Africa: The DART Trial
P Munderi*1, C Kityo Mutuluuza2, A Reid3, and A S Walker4
1MRC/UVRI Prgm. on AIDS, Entebbe, Uganda; 2Joint Clin. Res. Ctr., Kampala, Uganda; 3Univ. of Zimbabwe, Harare; and 4MRC Clin. Trials Unit, London, UK
593Persistence of X4-tropic Virus Despite Antiretroviral Treatment in Subtype C HIV
E Johnston*1, M Ketunuti1, R Kantor1, D Bhattacharaya1, L Zijenah2, and D Katzenstein1
1Stanford Univ., CA, USA and 2Univ. of Zimbabwe, Harare
594Mortality Is the Leading Cause of Loss to Follow-up among Antiretroviral Patients in Malawi
M Hosseinipour*1, F Neuhann2, C Kanyama1, D Namarika3, and S Phiri2
1Univ. of North Carolina Project, Lilongwe Malawi; 2Lighthouse Clin., Lilongwe, Malawi; and 3Lilongwe Central Hosp., Malawi
595A National Cohort Model for Assessing the Effect of an Expanded Access Program to Antiretroviral Therapy and the Short-term Predictors for Efficacy in a Middle-income Country
C Beltrán*, M Wolff, R Morales, and C Chahín
for the Chilean AIDS Cohort and CONASIDA, Chile
596
Challenges to Antiretroviral Drug Therapy in Resource-limited Settings: The Nigerian Experience
E Ekong*1, V Idemyor2, O Akinlade3, and A Uwah4
1Nigeria HIV/AIDS Res. Network, Lagos; 2Advocate Bethany Hosp., Chicago, IL, USA; 3Military Hosp., Ikoyi, Lagos, Nigeria; and 4Central Publ. Lab., Yaba, Lagos, Nigeria